Transchem
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
- Bakkt paid USD 9.41 million to subscribe for 47,500,000 Transchem warrants under a preferential allotment.
- Transchem’s Preferential Issue Committee allotted the warrants to Bakkt Opco Holdings on June 3, 2026.
- The payment represents 25% of the total subscription amount; the warrants can be exercised into Transchem ordinary shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bakkt Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-040634), on June 04, 2026, and is solely responsible for the information contained therein.
- Bakkt paid USD 9.41 million to subscribe for 47,500,000 Transchem warrants under a preferential allotment.
- Transchem’s Preferential Issue Committee allotted the warrants to Bakkt Opco Holdings on June 3, 2026.
- The payment represents 25% of the total subscription amount; the warrants can be exercised into Transchem ordinary shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bakkt Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-040634), on June 04, 2026, and is solely responsible for the information contained therein.
Jan 7 (Reuters) - Transchem Ltd TRAN.BO:
CFO MUKESH GARACH RESIGNS
Source text: ID:nBSE99Q5Sz
Further company coverage: TRAN.BO
(([email protected];;))
Jan 7 (Reuters) - Transchem Ltd TRAN.BO:
CFO MUKESH GARACH RESIGNS
Source text: ID:nBSE99Q5Sz
Further company coverage: TRAN.BO
(([email protected];;))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Transchem do?
Transchem Limited, originally focused on chemicals and pharmaceuticals, diversified into Mushroom production but due to changes in the horticulture scenario, its plant is currently non-operational.
Who are the competitors of Transchem?
Transchem major competitors are Harrisons Malayalam, Kotyark Industries, Sheetal Universal, Nath Bio-Genes (I), Mangalam Global Ent., Tierra Agrotech, SC Agrotech. Market Cap of Transchem is ₹426 Crs. While the median market cap of its peers are ₹339 Crs.
Is Transchem financially stable compared to its competitors?
Transchem seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Transchem pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Transchem latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Transchem allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Accounts Receivable
How strong is Transchem balance sheet?
Balance sheet of Transchem is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Transchem improving?
The profit is oscillating. The profit of Transchem is ₹2.93 Crs for TTM, ₹5.23 Crs for Mar 2025 and ₹4.2 Crs for Mar 2024.
Is the debt of Transchem increasing or decreasing?
Yes, The net debt of Transchem is increasing. Latest net debt of Transchem is -₹42.43 Crs as of Mar-26. This is greater than Mar-25 when it was -₹84.68 Crs.
Is Transchem stock expensive?
Transchem is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Transchem is 99.11, while 3 year average PE is 20.57. Also latest EV/EBITDA of Transchem is 0.0 while 3yr average is 0.71.
Has the share price of Transchem grown faster than its competition?
Transchem has given better returns compared to its competitors. Transchem has grown at ~123.52% over the last 2yrs while peers have grown at a median rate of 4.73%
Is the promoter bullish about Transchem?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Transchem is 56.45% and last quarter promoter holding is 56.45%.
Are mutual funds buying/selling Transchem?
There is Insufficient data to gauge this.